Targets › GRIA1
4 programs from 4 companies in 11 trials: 5 Phase 3, 4 Phase 1, 2 Phase 2; Psychiatry, Neurology; next expected readout Apr 2027.
Ionotropic glutamate receptor that functions as a ligand-gated cation channel, gated by L-glutamate and glutamatergic agonists such as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), quisqualic acid, and kainic acid. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. (UniProt, P42261)
Open in Phaseline: the race on GRIA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Neurocrine Biosciences | Osavampator (NBI-1065845) Glutamate receptor ionotropic AMPA positive allosteric modulator | GRIA4, GRIA3, GRIA2, GRIA1 | Phase 3 | Major Depressive Disorder | Jul 2027 |
| Eisai | Perampanel Glutamate receptor ionotropic AMPA antagonist | GRIA4, GRIA3, GRIA2, GRIA1 | Phase 2 | Pediatric Epileptic Syndrome; Depressive Disorder; Depression; Depressive Disorder, Major | Apr 2027 |
| Proniras | Tezampanel Glutamate receptor ionotropic AMPA antagonist; Glutamate receptor ionotropic kainate antagonist | GRIA4, GRIA3, GRIA2, GRIA1, GRIK1 | Phase 1 | Opioid Use Disorder | Oct 2027 |
| Carolyn Rodriguez | RR-HNK/Hydroxynorketamine AMPA receptor antagonist | GRIA1, GRIA2, GRIA3 | Phase 1 | Obsessive-Compulsive Disorder | Nov 2028 |
Major Depressive Disorder (5) Pediatric Epileptic Syndrome (1) Depressive Disorder (1) Depression (1) Depressive Disorder, Major (1) Obsessive-Compulsive Disorder (1) Opioid Use Disorder (1)
small molecule (4)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.